Literature DB >> 21276198

The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles.

M J Alkhatatbeh1, N M Mhaidat, A K Enjeti, L F Lincz, R F Thorne.   

Abstract

BACKGROUND: CD36 is a widely expressed cell surface receptor that binds lipoproteins, and its function has been implicated in many complications of the metabolic syndrome. A cell-free form of CD36, soluble CD36 (sCD36), has been reported in human plasma, found to be elevated in obesity and diabetes, and claimed as a marker of insulin resistance.
OBJECTIVE: To determine the nature of sCD36; in particular, whether sCD36 is truly soluble or, as hypothesized, is found as a component of circulating microparticles (MPs).
METHODS: Lipoproteins were fractionated by density gradient centrifugation, and plasma MPs were isolated by ultracentrifugation, size exclusion, and immunoprecipitation with CD36 detected by immunoblotting. MPs from plasma and activated platelets were analyzed by multicolor flow cytometry, with a DyLight-488 anti-CD36 conjugate in combination with antibodies against different cellular markers.
RESULTS: Cell-free plasma CD36 was not observed associated with lipoproteins and was not a proteolytic fragment; rather, it was associated with the plasma MP fraction, suggesting that sCD36 in the plasma of normal subjects is a product of circulating MPs. Cytometric and immunoblotting analyses of plasma from normal donors showed that these MPs were derived mainly from platelets. Analysis of in vitro activated platelets also showed that CD36 to be secreted in the form of MPs.
CONCLUSIONS: sCD36 is not a proteolytic product, but rather is associated with a specific subset of circulating MPs that can readily be analysed. This finding will enable more specific investigations into the cellular source of the increased levels of plasma CD36 found in subjects with diabetes.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21276198     DOI: 10.1111/j.1538-7836.2011.04220.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

Review 1.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

Review 2.  Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.

Authors:  Ying Wang; Li-ming Chen; Ming-lin Liu
Journal:  Acta Pharmacol Sin       Date:  2014-03-10       Impact factor: 6.150

3.  Bio-maleimide-stained plasma microparticles can be purified in a native state and target human proximal tubular HK2 cells.

Authors:  Mohammad J Alkhatatbeh; Lisa F Lincz; Rick F Thorne
Journal:  Biomed Rep       Date:  2016-11-09

4.  Circulating sCD36 levels in patients with non-alcoholic fatty liver disease and controls.

Authors:  S Heebøll; M K Poulsen; M J Ornstrup; T N Kjær; S B Pedersen; S Nielsen; H Grønbæk; A Handberg
Journal:  Int J Obes (Lond)       Date:  2016-12-05       Impact factor: 5.095

5.  Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype.

Authors:  Will S Driscoll; Tomas Vaisar; Jingjing Tang; Carole L Wilson; Elaine W Raines
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

Review 6.  Role of plasma kallikrein in diabetes and metabolism.

Authors:  E P Feener; Q Zhou; W Fickweiler
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

7.  Soluble cluster of differentiation 36 concentrations are not associated with cardiovascular risk factors in middle-aged subjects.

Authors:  Mohammad J Alkhatatbeh; Nehad M Ayoub; Nizar M Mhaidat; Nesreen A Saadeh; Lisa F Lincz
Journal:  Biomed Rep       Date:  2016-03-03

8.  Dynamics of circulating microparticles in obesity after weight loss.

Authors:  Elena Campello; Eva Zabeo; Claudia M Radu; Luca Spiezia; Mirto Foletto; Luca Prevedello; Sabrina Gavasso; Cristiana Bulato; Roberto Vettor; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2016-02-02       Impact factor: 3.397

9.  Circulating CD36 is increased in hyperlipidemic mice: Cellular sources and triggers of release.

Authors:  Sudipta Biswas; Detao Gao; Jessica B Altemus; Umar R Rekhi; Ellen Chang; Maria Febbraio; Tatiana V Byzova; Eugene A Podrez
Journal:  Free Radic Biol Med       Date:  2021-03-26       Impact factor: 7.376

10.  The origin of circulating CD36 in type 2 diabetes.

Authors:  M J Alkhatatbeh; A K Enjeti; S Acharya; R F Thorne; L F Lincz
Journal:  Nutr Diabetes       Date:  2013-02-04       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.